Related references
Note: Only part of the references are listed.Cerebrospinal fluid flow cytometry and risk of central nervous system relapse after hyperCVAD in adults with acute lymphoblastic leukemia
Kelsey-Leigh A. Garcia et al.
CANCER (2022)
High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse
Nicholas J. Short et al.
BLOOD ADVANCES (2022)
Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients
Caner Saygin et al.
HAEMATOLOGICA (2022)
CAR T cells in CNS-relapsed leukaemia: one step forward
Susanna Rives
Lancet Haematology (2021)
Acute Lymphoblastic Leukemia, Version 2.2021
Patrick A. Brown et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
Bijal D. Shah et al.
LANCET (2021)
Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms
Nicholas J. Short et al.
LEUKEMIA (2021)
Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia
Lori Muffly et al.
BLOOD ADVANCES (2021)
Flow cytometric detection of leukemic blasts in cerebrospinal fluid predicts risk of relapse in childhood acute lymphoblastic leukemia: a Nordic Society of Pediatric Hematology and Oncology study
Maria Thastrup et al.
LEUKEMIA (2020)
Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia
Aaron Kruse et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma
Travers Ching et al.
BMC CANCER (2020)
How I Approach the Patient Who Has MRD or Relapse After Transplant
Lori Muffly
Clinical Lymphoma Myeloma & Leukemia (2020)
Monitoring MRD in ALL: Methodologies, technical aspects and optimal time points for measurement
Jack Bartram et al.
SEMINARS IN HEMATOLOGY (2020)
Ultrasensitive Next-Generation Sequencing-Based Measurable Residual Disease Assessment in Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia after Frontline Therapy: Correlation with Flow Cytometry and Impact on Clinical Outcomes
Nicholas J. Short et al.
BLOOD (2020)
Multiparameter Flow Cytometry (MFC) of Cerebrospinal Fluid (CSF) from Adults Receiving Hypercvad for Acute Lymphoblastic Leukemia/Lymphoma (ALL) Identifies Patients at Higher Risk of Central Nervous System (CNS) Relapse: A Single-Center Retrospective Analysis
Kelsey-Leigh A. Garcia et al.
BLOOD (2020)
Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts
Nicholas J. Short et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403
Wendy Stock et al.
BLOOD (2019)
More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling
Peter Bader et al.
BLOOD ADVANCES (2019)
Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL
Brent Wood et al.
BLOOD (2018)
Clinical utility of next-generation sequencing-based minimal residual disease in paediatric B-cell acute lymphoblastic leukaemia
Yuko Sekiya et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia AMeta-analysis
Donald A. Berry et al.
JAMA ONCOLOGY (2017)
Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in older adults: Current treatment and novel therapies
Kristen M. O'Dwyer et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2017)
Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission
Naveen Pemmaraju et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
D. Hoelzer et al.
ANNALS OF ONCOLOGY (2016)
Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies
Jacques J. M. van Dongen et al.
BLOOD (2015)
Immunoglobulin and T Cell Receptor Gene High-Throughput Sequencing Quantifies Minimal Residual Disease in Acute Lymphoblastic Leukemia and Predicts Post-Transplantation Relapse and Survival
Aaron C. Logan et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation
Nicola Goekbuget et al.
BLOOD (2012)
Has MRD monitoring superseded other prognostic factors in adult ALL?
Monika Brueggemann et al.
BLOOD (2012)
Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment:: data from the GMALL 06/99 and 07/03 trials
Thorsten Raff et al.
BLOOD (2007)
Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL
VHJ van der Velden et al.
LEUKEMIA (2002)
Share Paper
